Your browser is no longer supported. Please, upgrade your browser.
Settings
NVO [NYSE]
Novo Nordisk A/S
Index- P/E33.34 EPS (ttm)3.04 Insider Own26.40% Shs Outstand2.30B Perf Week1.87%
Market Cap180.79B Forward P/E29.57 EPS next Y3.43 Insider Trans0.00% Shs Float1.22B Perf Month-2.50%
Income7.05B PEG24.09 EPS next Q0.77 Inst Own7.70% Short Float0.28% Perf Quarter23.25%
Sales20.66B P/S8.75 EPS this Y10.00% Inst Trans0.18% Short Ratio3.48 Perf Half Y44.15%
Book/sh4.53 P/B22.39 EPS next Y8.10% ROA30.40% Target Price- Perf Year45.77%
Cash/sh2.43 P/C41.77 EPS next 5Y1.38% ROE71.90% 52W Range63.22 - 107.24 Perf YTD45.18%
Dividend1.47 P/FCF41.96 EPS past 5Y5.90% ROI58.50% 52W High-5.44% Beta0.41
Dividend %1.45% Quick Ratio0.80 Sales past 5Y3.30% Gross Margin83.00% 52W Low60.41% ATR1.44
Employees45971 Current Ratio1.10 Sales Q/Q10.10% Oper. Margin41.40% RSI (14)54.57 Volatility1.22% 1.25%
OptionableYes Debt/Eq0.21 EPS Q/Q15.70% Profit Margin34.10% Rel Volume1.51 Prev Close102.38
ShortableYes LT Debt/Eq0.19 EarningsAug 05 BMO Payout292.60% Avg Volume996.53K Price101.41
Recom2.00 SMA20-0.62% SMA504.46% SMA20027.10% Volume1,500,767 Change-0.95%
Jan-20-21Downgrade Credit Suisse Outperform → Neutral
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Sep-17-19Upgrade Citigroup Neutral → Buy
Aug-30-19Downgrade Jefferies Hold → Underperform
Jun-20-19Downgrade Deutsche Bank Buy → Hold
Jun-11-19Upgrade Barclays Underweight → Equal Weight
Apr-29-19Upgrade Credit Suisse Neutral → Outperform
Jan-29-19Initiated Exane BNP Paribas Outperform
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-13-21 07:46AM  
Sep-09-21 11:07AM  
09:09AM  
Sep-06-21 07:45AM  
Aug-30-21 05:01AM  
Aug-25-21 12:39AM  
Aug-23-21 04:50AM  
Aug-20-21 02:34PM  
Aug-18-21 09:24AM  
Aug-16-21 09:10AM  
08:52AM  
Aug-12-21 01:24PM  
Aug-11-21 10:47AM  
08:04AM  
Aug-10-21 01:05PM  
07:20AM  
Aug-09-21 10:08AM  
Aug-07-21 10:02AM  
Aug-06-21 07:00PM  
09:30AM  
Aug-05-21 01:12PM  
04:45AM  
03:04AM  
Aug-04-21 10:41AM  
10:24AM  
05:39AM  
Jul-30-21 12:31PM  
Jul-26-21 04:36PM  
07:01AM  
Jul-24-21 09:31AM  
Jul-20-21 12:11AM  
Jul-19-21 05:56AM  
Jul-16-21 07:18AM  
Jul-13-21 12:22PM  
Jul-12-21 12:45PM  
08:30AM  
07:30AM  
07:08AM  
07:00AM  
Jul-05-21 11:40AM  
08:51AM  
Jun-29-21 03:33PM  
01:06PM  
09:03AM  
08:51AM  
08:20AM  
Jun-28-21 09:12AM  
06:49AM  
Jun-26-21 04:30PM  
Jun-21-21 10:05AM  
Jun-16-21 01:06PM  
Jun-14-21 08:27AM  
07:48AM  
Jun-11-21 01:26PM  
08:41AM  
Jun-07-21 08:50AM  
08:15AM  
07:46AM  
04:32AM  
02:49AM  
Jun-04-21 04:36PM  
02:47PM  
02:10PM  
Jun-02-21 01:44AM  
Jun-01-21 10:29AM  
May-31-21 07:47AM  
May-28-21 12:52PM  
10:17AM  
May-25-21 09:06AM  
May-21-21 09:06AM  
May-20-21 02:58PM  
May-19-21 06:30AM  
May-17-21 10:30AM  
May-13-21 04:26PM  
May-07-21 03:54PM  
03:31PM  
03:24PM  
11:40AM  
May-06-21 05:47AM  
May-05-21 07:30PM  
10:45AM  
09:15AM  
02:13AM  
01:30AM  
May-04-21 10:38AM  
Apr-29-21 05:00AM  
Apr-27-21 09:22AM  
09:14AM  
Apr-26-21 05:05AM  
Apr-24-21 08:48AM  
Apr-22-21 08:44AM  
Apr-21-21 01:53PM  
09:52AM  
Apr-20-21 06:53AM  
Apr-19-21 05:37AM  
Apr-12-21 09:18AM  
Apr-05-21 07:43AM  
Apr-01-21 04:46PM  
Mar-30-21 11:45AM  
Mar-29-21 04:56AM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.